TriSalus Life Sciences, Inc.
TLSI
$5.10
$0.173.45%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | 35.99M | 32.14M | 29.43M | 26.89M | 24.74M |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 35.99M | 32.14M | 29.43M | 26.89M | 24.74M |
Cost of Revenue | 5.52M | 4.63M | 4.10M | 3.47M | 3.05M |
Gross Profit | 30.47M | 27.51M | 25.33M | 23.42M | 21.68M |
SG&A Expenses | 47.06M | 44.20M | 43.81M | 42.04M | 42.31M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 66.97M | 63.96M | 65.60M | 68.01M | 73.15M |
Operating Income | -30.98M | -31.82M | -36.17M | -41.12M | -48.41M |
Income Before Tax | -31.17M | -27.21M | -30.04M | -55.57M | -54.59M |
Income Tax Expenses | -2.00K | 8.00K | 6.00K | 8.00K | 11.00K |
Earnings from Continuing Operations | -31.17 | -27.21 | -30.05 | -55.58 | -54.60 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -31.17M | -27.21M | -30.05M | -55.58M | -54.60M |
EBIT | -30.98M | -31.82M | -36.17M | -41.12M | -48.41M |
EBITDA | -30.28M | -31.09M | -35.43M | -40.39M | -47.69M |
EPS Basic | -1.18 | -1.12 | -1.33 | -2.50 | -2.53 |
Normalized Basic EPS | -0.70 | -1.00 | -1.04 | -1.49 | -2.23 |
EPS Diluted | -1.18 | -1.12 | -1.33 | -2.50 | -2.53 |
Normalized Diluted EPS | -0.70 | -1.00 | -1.04 | -1.49 | -2.23 |
Average Basic Shares Outstanding | 115.48M | 106.48M | 101.28M | 96.96M | 83.63M |
Average Diluted Shares Outstanding | 115.48M | 106.48M | 101.28M | 96.96M | 83.63M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |